Key Performance
More- Earnings Score: N/A
- Momentum Score: 79
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
NewAmsterdam Pharma announced it will present multiple data presentations on obicetrapib, its novel oral CETP inhibitor for cholesterol management, at the NLA 2026 Scientific Sessions in Chicago on June 11-14, 2026. The presentations will cover clinical trial safety assessments, efficacy data from Phase 3 trials (BROADWAY and BROOKLYN), and real-world evidence on statin intolerance. The company has also granted European commercialization rights to the Menarini Group.
06/03/2026, 8:00 AM • GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma announced that company management will participate in investor conferences including the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company is developing obicetrapib, an oral CETP inhibitor, for LDL-C lowering in cardiovascular disease patients, with regulatory decisions from EMA, UK, and Switzerland expected in the second half of 2026.
05/28/2026, 8:00 AM • GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma's Compensation Committee approved inducement grants of 50,400 share options and 15,400 restricted stock units to five new non-executive employees. The options have an exercise price of $28.43 per share with four-year vesting, while RSUs vest over three years. These grants were made under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
05/01/2026, 4:57 PM • GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma's Compensation Committee approved inducement grants of 15,000 share options and 3,200 restricted stock units to two non-executive new hires. The options have an exercise price of $32.81 per share with four-year vesting, while RSUs vest over three years. Both grants were made under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
04/02/2026, 5:43 PM • GlobeNewswire
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
NewAmsterdam Pharma announced that its CFO Ian Somaiya and EVP of Investor Relations Matthew Philippe will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company is a late-stage biopharmaceutical firm developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients, with EMA approval decisions expected in H2 2026.
02/04/2026, 8:00 AM • GlobeNewswire
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
NewAmsterdam Pharma reported Q2 2025 earnings with $19.1 million in revenue, exceeding consensus estimates. The company showed progress in clinical trials for obicetrapib, a cholesterol-lowering therapy, and maintained strong cash reserves while preparing for potential European market entry.
08/06/2025, 8:21 PM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.